MorphoSys AG (MOR) Receives €67.00 Average PT from Analysts

MorphoSys AG (ETR:MOR) has received a consensus recommendation of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is €69.57 ($81.85).

Receive News & Ratings for MorphoSys AG Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.

A number of research analysts have weighed in on the stock. Independent Research GmbH set a €77.00 ($90.59) price target on shares of MorphoSys AG and gave the company a “buy” rating in a research note on Monday, May 29th. Berenberg Bank set a €68.00 ($80.00) price objective on shares of MorphoSys AG and gave the company a “buy” rating in a report on Thursday, May 25th. J P Morgan Chase & Co restated a “neutral” rating on shares of MorphoSys AG in a research note on Monday, July 17th. Commerzbank Ag set a €76.00 ($89.41) price objective on shares of MorphoSys AG and gave the stock a “buy” rating in a research note on Tuesday, May 30th. Finally, HSBC Holdings plc set a €59.00 ($69.41) price objective on shares of MorphoSys AG and gave the stock a “neutral” rating in a research note on Friday, July 14th.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by [[site]] and is owned by of [[site]]. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at [[permalink]].

Shares of MorphoSys AG (MOR) opened at 59.944 on Monday. MorphoSys AG has a 12 month low of €35.72 and a 12 month high of €70.90. The company has a 50 day moving average of €62.74 and a 200 day moving average of €57.44. The stock’s market cap is €1.72 billion.

MorphoSys AG Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.